New cocktail aims to tame metastatic prostate cancer
NCT ID NCT03821792
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of abiraterone, prednisone, and apalutamide in 60 men with hormone-naïve metastatic prostate cancer. The goal is to see how long patients can stay on treatment and how well it controls the cancer. All three drugs work by lowering or blocking male hormones that fuel prostate cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Abiraterone acetate, prednisone, and apalutamide
- What this could lead to
- If successful, this combination could offer a new way to control metastatic prostate cancer by blocking androgen production and activity.
- What could go wrong
- This is a small, early-phase trial (60 participants) with no control group, so results may not confirm effectiveness. Side effects from the drugs can include fatigue, high blood pressure, and liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can a better scan sharpen radiation for prostate cancer?
- Hormone therapy showdown: can an oral pill beat the shot for prostate cancer patients?
- Can tracking tumor movement during radiation make treatment more precise?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?